Soficabtagene geleucel - Wugen
Alternative Names: Allogenic CAR-T cell therapies - Wugen; Anti-CD7 Allogeneic CAR T Cells - Wugen; WU-CART-007Latest Information Update: 09 Dec 2025
At a glance
- Originator WUGEN
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Yes - Precursor T-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Precursor T-cell lymphoblastic leukaemia-lymphoma
- Phase I/II Precursor cell lymphoblastic leukaemia-lymphoma
- Phase I Haematological malignancies
Most Recent Events
- 05 Dec 2025 Pharmacokinetics, pharmacodynamics and adverse events data from a phase I/II trial in Precursor cell lymphoblastic leukaemia-lymphoma and Precursor T cell lymphoblastic leukaemia lymphoma released by WUGEN
- 27 Aug 2025 Wugen plans to file Biologics License Application (BLA) for Precursor T-cell lymphoblastic leukaemia-lymphoma, Precursor cell lymphoblastic leukaemia-lymphoma in 2027
- 31 Jan 2025 Phase-II clinical trials in Precursor T-cell lymphoblastic leukaemia-lymphoma (Second-line therapy or greater, In infants, In children, In adolescents, In adults, In the elderly) in USA (IV) (NCT06514794)